Development

A failed trial reframes Alzheimer's as metabolic

development2026-01-03

Claim

The failure of Novo Nordisk's EVOKE trial redirected GLP-1 Alzheimer's work toward combination therapies treating dementia as a metabolic disorder.

Reporting date: 2026-01-03 (not necessarily the event date)

Sources

Attribution and reporting linked by this record; links do not imply independent verification.

Welcome to January 3, 2026 (theinnermostloop.substack.com)

Knowledge graphopen in browser →

Reported in

Welcome to January 3, 2026

Actor

Novo Nordisk

Evidence for

Discovery becomes industrial process

Referenced by

Cite or correct this record

Citation formatCitation text

A failed trial reframes Alzheimer's as metabolic
Innermost Loop KB — secondary record
Reporting date: 2026-01-03
KB permalink: https://nicholsn.github.io/innermost-loop-kb/developments/2026-01-03-evoke-failure-reframes-alzheimers
Claim: The failure of Novo Nordisk's EVOKE trial redirected GLP-1 Alzheimer's work toward combination therapies treating dementia as a metabolic disorder.
Attributed sources:
- Welcome to January 3, 2026 — https://theinnermostloop.substack.com/p/welcome-to-january-3-2026
This citation does not imply independent verification of linked-source claims.

Suggest a correction — opens a GitHub draft for you to review and submit.